title: [The alpha chemokine "Interferon gamma-induced protein 10" (IP-10) in Graves' disease and Graves'ophthalmopathy].
abstract: Interferon(IFN)γ-induced protein 10 (IP-10) and its receptor, CXC receptor 3, appear to contribute to the pathogenesis of Graves' disease (GD) and Graves' ophthalmopathy (GO). Under the influence of IFN-γ, IP-10 is secreted by thyrocytes (in GD), fibroblasts and preadipocytes (in GO). Determination of high level of IP-10 in peripheral liquids is therefore a marker of a Th1 orientated immune response. Circulating IP-10 is associated with the active phase of GD in both newly diagnosed and relapsing hyperthyroid patients. Methimazole reduces IP-10 secretion by isolated thyrocytes, decreases serum IP-10 levels, and promotes a transition from Th1 to Th2 dominance in patients with GD active phase. In GD patients the decrease of IP-10 after thyroidectomy and radioiodine strongly suggests that this chemokine is mainly produced by the thyroid itself. In GO patients the increased concentrations of IP-10, at least in part, reflect the activity of orbital inflammation. A significant reductions in IP-10 serum concentrations during corticosteroids and or radiotherapy treatments, as compared both to control group and to basal values in GO patients, suggest that this chemokine could serve as a guideline in therapeutic decision-making in patients with GO. Further studies are needed to evaluate whether IP-10 is a novel therapeutic target in GD and GO.
authors.affiliation: Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa.
authors.forename: A
authors.initials: A
authors.lastname: Di Domenicantonio
authors.affiliation: Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa.
authors.forename: U
authors.initials: U
authors.lastname: Politti
authors.affiliation: Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto, Università di Modena e Reggio Emilia, Modena, Italy.
authors.forename: D
authors.initials: D
authors.lastname: Giuggioli
authors.affiliation: Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa.
authors.forename: A
authors.initials: A
authors.lastname: Antonelli
authors.affiliation: Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto, Università di Modena e Reggio Emilia, Modena, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Ferri
authors.affiliation: Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa.
authors.forename: P
authors.initials: P
authors.lastname: Fallahi
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D054357:Chemokine CXCL10 / Q000097:blood / Q000378:metabolism*; D006111:Graves Disease / Q000378:metabolism* / Q000601:surgery; D049970:Graves Ophthalmopathy / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008713:Methimazole / Q000494:pharmacology; D013965:Thyroidectomy
chemical_list: D000305:Adrenal Cortex Hormones; C114753:CXCL10 protein, human; D054357:Chemokine CXCL10; D007457:Iodine Radioisotopes; D008713:Methimazole